320 related articles for article (PubMed ID: 27116020)
1. Implementing the Biopharmaceutics Classification System in Drug Development: Reconciling Similarities, Differences, and Shared Challenges in the EMA and US-FDA-Recommended Approaches.
Cardot JM; Garcia Arieta A; Paixao P; Tasevska I; Davit B
AAPS J; 2016 Jul; 18(4):1039-46. PubMed ID: 27116020
[TBL] [Abstract][Full Text] [Related]
2. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
Davit BM; Kanfer I; Tsang YC; Cardot JM
AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
[TBL] [Abstract][Full Text] [Related]
3. Implementing the additional strength biowaiver for generics: EMA recommended approaches and challenges for a US-FDA submission.
Cardot JM; Garcia-Arieta A; Paixao P; Tasevska I; Davit B
Eur J Pharm Sci; 2018 Jan; 111():399-408. PubMed ID: 29032306
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
5. The impact of the EMA change in definition of "dose" on the BCS dose-solubility ratio: a review of the biowaiver monographs.
Sediq A; Kubbinga M; Langguth P; Dressman J
J Pharm Sci; 2014 Jan; 103(1):65-70. PubMed ID: 24338749
[TBL] [Abstract][Full Text] [Related]
6. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.
Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX
Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742
[TBL] [Abstract][Full Text] [Related]
7. The Discriminatory Power of the BCS-Based Biowaiver: A Retrospective With Focus on Essential Medicines.
Hofsäss MA; Dressman JB
J Pharm Sci; 2019 Sep; 108(9):2824-2837. PubMed ID: 31059698
[TBL] [Abstract][Full Text] [Related]
8. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
[TBL] [Abstract][Full Text] [Related]
9. Biopharmaceutics classification system-based biowaivers for generic oncology drug products: case studies.
Tampal N; Mandula H; Zhang H; Li BV; Nguyen H; Conner DP
AAPS PharmSciTech; 2015 Feb; 16(1):5-9. PubMed ID: 25245330
[TBL] [Abstract][Full Text] [Related]
10. Biopharmaceutics classification system: the scientific basis for biowaiver extensions.
Yu LX; Amidon GL; Polli JE; Zhao H; Mehta MU; Conner DP; Shah VP; Lesko LJ; Chen ML; Lee VH; Hussain AS
Pharm Res; 2002 Jul; 19(7):921-5. PubMed ID: 12180542
[TBL] [Abstract][Full Text] [Related]
11. The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted.
Benet LZ; Larregieu CA
Clin Pharmacol Ther; 2010 Sep; 88(3):405-7. PubMed ID: 20668447
[TBL] [Abstract][Full Text] [Related]
12. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Isavuconazonium Sulfate.
Plano D; Rudolph N; Saal C; Abrahamsson B; Cristofoletti R; Kambayashi A; Langguth P; Mehta M; Parr A; Polli JE; Shah VP; Charoo N; Dressman J
J Pharm Sci; 2024 Feb; 113(2):386-395. PubMed ID: 37951471
[TBL] [Abstract][Full Text] [Related]
13. Scientific considerations concerning the EMA change in the definition of "dose" of the BCS-based biowaiver guideline and implications for bioequivalence.
Daousani C; Macheras P
Int J Pharm; 2015 Jan; 478(2):606-9. PubMed ID: 25437115
[TBL] [Abstract][Full Text] [Related]
14. Biowaiver monographs for immediate-release solid oral dosage forms: codeine phosphate.
Dahan A; Wolk O; Zur M; Amidon GL; Abrahamsson B; Cristofoletti R; Groot DW; Kopp S; Langguth P; Polli JE; Shah VP; Dressman JB
J Pharm Sci; 2014 Jun; 103(6):1592-600. PubMed ID: 24788239
[TBL] [Abstract][Full Text] [Related]
15. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Amoxicillin Trihydrate.
Thambavita D; Galappatthy P; Mannapperuma U; Jayakody L; Cristofoletti R; Abrahamsson B; Groot DW; Langguth P; Mehta M; Parr A; Polli JE; Shah VP; Dressman J
J Pharm Sci; 2017 Oct; 106(10):2930-2945. PubMed ID: 28483422
[TBL] [Abstract][Full Text] [Related]
16. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Sitagliptin Phosphate Monohydrate.
Charoo NA; Abdallah DB; Bakheit AA; Haque KU; Hassan HA; Abrahamsson B; Cristofoletti R; Langguth P; Mehta M; Parr A; Polli JE; Shah VP; Tajiri T; Dressman J
J Pharm Sci; 2022 Jan; 111(1):2-13. PubMed ID: 34597625
[TBL] [Abstract][Full Text] [Related]
17. Policy of Multisource Drug Products in Latin America: Opportunities and Challenges on the Application of Bioequivalence In Vitro Assays.
Miranda-Pérez de Alejo C; Aceituno Álvarez A; Mendes Lima Santos G; Fernández Cervera M; Jung-Cook H; Cabrera-Pérez MÁ
Ther Innov Regul Sci; 2021 Jan; 55(1):65-81. PubMed ID: 32602028
[TBL] [Abstract][Full Text] [Related]
18. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Moxifloxacin Hydrochloride.
Charoo NA; Abdallah DB; Parveen T; Abrahamsson B; Cristofoletti R; Groot DW; Langguth P; Parr A; Polli JE; Mehta M; Shah VP; Tajiri T; Dressman J
J Pharm Sci; 2020 Sep; 109(9):2654-2675. PubMed ID: 32534881
[TBL] [Abstract][Full Text] [Related]
19. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Fexofenadine.
Charoo NA; Selvasudha N; Kath ZN; Abrahamsson B; Cristofoletti R; Kambayashi A; Langguth P; Mehta M; Parr A; Polli JE; Shah VP; Dressman J
J Pharm Sci; 2024 Jun; ():. PubMed ID: 38857646
[TBL] [Abstract][Full Text] [Related]
20. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cephalexin Monohydrate.
Plöger GF; Quizon PM; Abrahamsson B; Cristofoletti R; Groot DW; Parr A; Langguth P; Polli JE; Shah VP; Tajiri T; Mehta MU; Dressman J
J Pharm Sci; 2020 Jun; 109(6):1846-1862. PubMed ID: 32240696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
